Home » Stocks » PTPI

Petros Pharmaceuticals, Inc. (PTPI)

Stock Price: $3.08 USD -0.13 (-4.05%)
Updated May 12, 2021 3:27 PM EDT - Market closed
Market Cap 33.85M
Revenue (ttm) 9.56M
Net Income (ttm) -20.59M
Shares Out 9.77M
EPS (ttm) -3.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $3.08
Previous Close $3.21
Change ($) -0.13
Change (%) -4.05%
Day's Open 3.22
Day's Range 3.00 - 3.35
Day's Volume 17,394
52-Week Range 1.80 - 5.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set the ...

Other stocks mentioned: NTRP
5 months ago - PRNewsWire

NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovati...

Other stocks mentioned: NTRP
7 months ago - PRNewsWire

NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused...

Other stocks mentioned: NTRP
11 months ago - PRNewsWire

Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.

Other stocks mentioned: NTRP
1 year ago - Benzinga

It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply with a drug study update from eve...

Other stocks mentioned: NTRP
1 year ago - 24/7 Wall Street

Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's disease (AD) ...

Other stocks mentioned: NTRP
1 year ago - Market Watch

Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.

Other stocks mentioned: NTRP
1 year ago - Benzinga

Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.

Other stocks mentioned: NTRP
1 year ago - Zacks Investment Research

Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.

Other stocks mentioned: NTRP
1 year ago - Zacks Investment Research

The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare.

Other stocks mentioned: AVXL, NTRP
1 year ago - 24/7 Wall Street

Neurotrope, Inc. may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. suffered handily with the announcement that it and partner Eisei were halting late-stage...

Other stocks mentioned: NTRP
2 years ago - 24/7 Wall Street

About PTPI

Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based... [Read more...]

Industry
Biotechnology
Founded
2020
Stock Exchange
NASDAQ
Ticker Symbol
PTPI
Full Company Profile

Financial Performance

In 2020, PTPI's revenue was $9.56 million, a decrease of -38.63% compared to the previous year's $15.58 million. Losses were -$20.59 million, -36.68% less than in 2019.

Financial Statements